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Abstract: Cell viability studies for benzo[1,2,4]triazin-7-ones and 1,2,4-benzotriazinyl (Blatter-type)
radical precursors are described with comparisons made with 2,2,6,6-tetramethyl-1-piperidinyloxy
(TEMPO). All of the stable free radicals were several orders of magnitude less cytotoxic than
the benzo[1,2,4] triazin-7-ones. The synthesis and evaluation of two new pyrid-2-yl benzo[1,2,4]
triazin-7-ones are described, where altering the 1,3-substitution from phenyl to pyrid-2-yl increased
cytotoxicity against most cancer cell lines, as indicated using National Cancer Institute (NCI) one-dose
testing. COMPARE analysis of five-dose testing data from the NCI showed very strong correlations
to the naturally occurring anti-cancer compound pleurotin. COMPARE is program, which analyzes
similarities in cytotoxicity data of compounds, and enables quantitative expression as Pearson
correlation coefficients. Compounds were also evaluated using the independent MTT assay, which
was compared with SRB assay data generated at the NCI.
Keywords: anti-tumour; blatter-type radical; heterocyclic compound; NCI; pleurotin; TEMPO
1. Introduction
The cytotoxicity of the 3-substituted 1-phenylbenzo[1,2,4]triazin-7-ones 1 and 2 (Figure 1) showed
very strong correlation (Pearson correlation coefficients ~0.8) to the naturally occurring antibiotic and
anti-cancer agent pleurotin using the National Cancer Institute (NCI) COMPARE analysis. The origin
for the anti-cancer activity is likely to be thioredoxin reductase (TrxR) inhibition, with the 3-Ph 1
and 3-F3C 2 substituted benzotriazinones exhibiting strong reversible mixed and uncompetitive
inhibition [1]. Our anti-cancer studies followed evidence that analogues of scaffold 1 were multi-target
inhibitors of Alzheimer’s disease [2]. Benzotriazinones are easily prepared by treating Blatter-type
(benzotriazin-4-yl) radicals with manganese dioxide in dichloromethane at room temperature
(Scheme 1) [3]. Given that stable free radicals such as 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO)
have shown cytotoxicity, including against breast (MDA-MB 231) [4] and prostate cancer (DU-145)
cell lines [5], in this article we investigate the cytotoxicity of benzotriazin-4-yl radicals 3a and 3b
and contrast them with the oxidation products 4a and 4b. Herein, we report the synthesis and
cytotoxicity evaluation of new benzotriazinones, 3-phenyl-1-(pyrid-2-yl)benzo[1,2,4]triazin-7-one
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(4a) and 1-phenyl-3-(pyrid-2-yl)benzo[1,2,4]triazin-7-one (4b). Incorporating pyridine is reported to
significantly alter cytotoxicity against certain cancer cell lines, hence we made the choice of replacing
phenyl in the parent structure 1 with the pyrid-2-yl substituent in 4a and 4b [6–8].
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Radicals 3a and 3b were not selected by the NCI for cytotoxicity evaluation, although 
benzotriazinones 4a and 4b were used for one-dose (10 µM) screening against the DTP 60 cell line 
panel. Pyrid-2-yl-substituted compounds 4a and 4b exhibited similar variable cytotoxicity profiles, 
with overall cytotoxicity greater than the 1,3-diphenyl-substituted compound 1 [1] against most of 
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Pyridyl-substituted compounds 4a and 4b, however, showed little growth inhibition of the DU-145 
(prostate cancer) cell line after one-dose testing in comparison to 1. However, IC50 values after NCI 
five-dose testing (see below) showed that 4b had comparable cytotoxicity to 1, with 4a being over 
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2. Results and Discussion
2.1. Synthesis of Pyrid-2-yl-Substituted Benzo[1,2,4]triazin-7-ones
The preparation of benzotriazinyl radicals 3a and 3b has previously been reported [9]. New
pyridyl-substituted benzotriazinones 4a and 4b were prepared from the MnO2-mediated oxidation [3]
of benzotriazin-4-yls 3a a d 3b in 90 and 46% yields, respectively (Scheme 1). It should be noted
that 1,3-b s(pyrid-2-yl)benzo[1,2,4]triazin-7-one is derived from the MnO2-mediated oxidation of
1,3-bis(pyrid-2-yl)-1,4-dihy ro-1,2,4-benzotriazine (i.e., th 4-NH, and not the free radical). However,
the latter di-substituted pyrid-2-yl deriva ive was n t selected for evaluation at the National Cancer
Institute (NCI, see below), and thus is not a subject of the present article.
2.2. D velopment Therapeutic Program (DTP) National Cancer Institute (NCI) 60 Human Tumor Cell Line
Screen and COMPARE Analysis
Radicals 3a and 3b were not sel cted by the NCI for cytotoxicity valuation, although benzotriazi ones
4a and 4b were used for on -dose (10 µM) screening against the DTP 60 cell line panel. Pyrid-2-yl-
substituted compounds 4a and 4b exhibited similar variable cytotoxicity profiles, with overall
cytotoxicity greater than the 1,3-diphenyl-substituted compound 1 [1] against most of the nine major
histological tissue types at the NCI DTP (Figure 2). There was particularly strong growth inhibition
exhibited by 4a and 4b in certain cancer cell lines, NCI-H522 (non-small cell lung cancer), COLO 205
(colon cancer), HT29 (c lon cancer), SW-620 (colon cancer), ACHN (renal ca cer), TK-10 (renal cancer),
T-47D (br ast cancer), MDA-MB-468 (brea cancer), and MCF-7 (breast cancer). Pyridyl-substituted
compounds 4a and 4b, however, showed little growth inhi ition f the DU-145 (prostat cancer) cell
line after one-dose testing in comparison to 1. However, IC50 values after NCI five-dose testing (see
below) showed that 4b had comparable cytotoxicity to 1, with 4a being over eight times less cytotoxic
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than 1 against the DU-145 cell line (Table 1). The DU-145 and MCF-7 cell lines were available to us
(see below), and the MTT assay was used to obtain independent IC50 values.
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Figure 2. Summary of Developme t Therapeutic Program (DTP) Natio al Cancer Institute (NCI)-single
dose (10 µM) screening results for be zo[1,2,4]triazi -7-ones 1 (green), 4a (red), and 4b (blue) expressed
as an average percent growth of each cancer cell type or certain cancer cell line relative to untreated
cancer cells.
Table 1. NCI IC50 data after five-dose testing: DMSO solution of compound (100 µL) was added to
plates, which were incubated for 48 h at 37 ◦C using 5% CO2 (humidified atmosphere). Sulforhodamine
B (SRB) assay was used to evaluate cytotoxicity.




The NCI selection of 4a and 4b for subsequent five-dose testing established key parameters used
in the NCI COMPARE algorithm to determine closely matching cytotoxicity profiles [1,10] (complete
one- and five-dose data for 4a and 4b can be found in the Supplementary Information accompanying
this article). The COMPARE analysis facilitated comparisons of cytotoxicity with the NCI’s vast
database of over 250,000 synthetic compounds. The degree of similarity between two cytotoxicity
profiles is described by the Pearson product-moment correlation coefficient (0 to ±1), with values
above ±0.5 considered to be strong. On par with the Pearson correlation coefficient of 1 [1], very
strong correlations to pleurotin of 0.84 and 0.73 were obtained for 4a and 4b, respectively (Table 2).
Altering the 1,3-substitution from Ph to pyrid-2-yl in the benzo[1,2,4]triazin-7-one scaffold did not
appear to alter the compound’s mechanism of action, with cytotoxicity profiles closely matching that
of the irreversible TrxR inhibitor pleurotin.
Molecules 2018, 23, 574 4 of 8





2.3. Cytotoxicity against DU-145 and MCF-7 Cell Lines Using the MTT Assay
The DU-145 (prostate cancer) and MCF-7 (breast cancer) cell lines, available at the National
University of Ireland Galway (NUI Galway), were used to independently determine IC50 values.
The cytotoxicity of benzotriazin-4-yl radicals 3a and 3b, TEMPO, and iminoquinones 4a and 4b was
determined using the MTT assay. Radicals 3a and 3b exhibited very similar cytotoxicity profiles (see
Supplementary Information), and were on average 13 and 105 times less cytotoxic towards the DU-145
and MCF-7 cell lines than oxidation products 4a and 4b (Table 3). Radicals 3a and 3b exhibited an
approximate 10-fold greater cytotoxicity towards the prostate cancer compared to the breast cancer cell
line. Benzotriazinones 4a and 4b gave similar submicromolar IC50 values against both cell lines, which
were similar in magnitude to that of the previously evaluated compound 1 using the MTT assay [1].
In comparison, TEMPO was found to be relatively non-toxic. This is perhaps not surprising given
that high concentrations of TEMPO (of 2.5 mM for 24 h) were required in order to induce a 3.4-fold
increase in both early apoptotic cells and late apoptotic/necrotic cells compared with untreated DU-145
cell controls [5]. Literature reports support the requirement for high concentrations (2.5–10 mM) of
nitroxide radicals (such as TEMPO) to achieve a therapeutic dose against various breast and prostate
cancer cell lines [4,5]. Nevertheless, all radicals were significantly more cytotoxic towards the DU-145
cell line than the MCF-7 cell line.
Table 3. Cytotoxicity evaluation (NUI Galway) using the MTT colorimetric assay. IC50 values were
obtained after the incubation of cells with the test compounds in DMSO for 72 h. IC50 for 1 were
previously obtained under identical conditions [1].
Compound IC50 DU-145 (µM) IC50 MCF-7 (µM)
1 0.230 ± 0.03 0.810 ± 0.08
TEMPO 151.400 ± 7.480 >999
3a 3.140 ± 0.179 34.740 ± 6.236
3b 3.177 ± 0.154 26.415 ± 2.538
4a 0.245 ± 0.003 0.303 ± 0.009
4b 0.241 ± 0.011 0.277 ± 0.002
Using the MTT assay (Table 3), 1, 4a, and 4b exhibited greater cytotoxicity towards DU-145
and MCF-7 cell lines than that shown by the NCI five-dose data (except for 1 against MCF-7 at
the NCI Table 1). The discrepancies in IC50 values were expected given the longer exposure time
of cancer cells to the cytotoxic agent in the MTT assay (72 h versus 48 h at the NCI), as well as
fundamental differences in the assays [11–13]. The SRB assay used by the NCI measures the amount
of dye (sulforhodamine B) bound onto cellular protein, and is reported to be more sensitive than




Reactions were protected from atmospheric moisture using CaCl2 drying tubes. All volatiles
were removed under reduced pressure. All reaction mixtures and column eluents were monitored by
TLC (thin layer chromatography) using commercial glass-backed thin layer chromatography (TLC)
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plates (Merck Kieselgel 60 F254, Darmstadt, Germany). The plates were observed under UV light at
254 and 365 nm. The technique of dry flash chromatography was used throughout for all non-TLC
scale chromatographic separations using Merck Silica Gel 60 (less than 0.063 mm) (Merck, Darmstadt,
Germany) [14]. Melting and decomposition points were determined using either a PolyTherm-A,
Wagner & Munz, Kofler-Hotstage Microscope apparatus (Wagner & Munz, Munich, Germany) or
a TA Instruments DSC Q1000 (TA Instrument, New Castle, DE, USA) with samples hermetically
sealed in aluminum pans under an argon atmosphere, using heating rates of 5 ◦C/min. Solvents
used for recrystallization are indicated after the melting point. UV spectra were obtained using a
Shimadzu UV-1601 UV/Vis spectrophotometer (Shimadzu, Kyoto, Japan) and inflections are identified
by the abbreviation “inf”. IR spectra were recorded on a Shimadzu FTIR-NIR Prestige-21 spectrometer
(Shimadzu, Kyoto, Japan) with a Pike Miracle Ge ATR accessory and strong, medium, and weak peaks
are represented by s, m, and w, respectively. 1H and 13C-NMR spectra were recorded on a Bruker
Avance 500 machine (at 500 and 125 MHz, respectively) (Bruker, Billerica, MA, USA). Deuterated
solvents were used for homonuclear lock and the signals are referenced to the deuterated solvent
peaks. MALDI-TOF MS was conducted on a Bruker BIFLEX III time-of-flight (TOF) mass spectrometer
(Bruker, Billerica, MA, USA). 3-Phenyl-1-(pyrid-2-yl)-1,4-dihydrobenzo[e][1,2,4]triazin-4-yl (3a)
and 1-phenyl-3-(pyrid-2-yl)-1,4-dihydrobenzo[e][1,2,4]triazin-4-yl (3b) were prepared according to
literature procedures [9].
3.2. Synthesis of Phenyl- and Pyrid-2-yl-Substituted Benzo[1,2,4]triazin-7-ones 4a and 4b
3-Phenyl-1-(pyrid-2-yl)benzo[e][1,2,4]triazin-7(1H)-one (4a). To a stirred solution of 3-phenyl-1-(pyrid-2-
yl)-1,4-dihydro-1,2,4-benzotriazin-4-yl (3a) (285 mg, 1.0 mmol) in dichloromethane (10 mL), MnO2
(869 mg, 10.0 mmol) was added and the reaction mixture was stirred at ca. 20 ◦C for two days. The
reaction mixture was filtered through Celite® (Honeywell Specialty Chemicals Seelze GmbH, Seelze,
Germany), rinsed with additional dichloromethane (50 mL), and volatiles were removed in vacuo.
The residue was chromatographed on a short pad of silica with tert-butyl methyl ether (TBME) to
give the title compound 4a (270 mg, 90%) as purple needles, m.p. (hot-stage): 210.1–213.8 ◦C (from
PhH); m.p. (DSC) onset: 209.9 ◦C, peak max: 210.5 ◦C, decomp. onset: 225.8 ◦C, decomp. peak max:
227.7 ◦C (from PhH); Rf 0.58 (TBME, 100%); found: C, 71.87; H, 4.12; N, 18.70. C18H12N4O requires C,
71.99; H, 4.03; N, 18.66%; λmax(DCM)/nm 295 (logε 4.58), 310 inf (4.46), 339 inf (3.91), 356 inf (3.91),
544 (3.75), 582 (3.70), 635 inf (3.33); νmax/cm−1 3073w (aryl C-H), 1624s, 1599s, 1587s, 1570m, 1547s,
1526m, 1497w, 1468m, 1437s, 1398w, 1385w, 1333w, 1310w, 1281w, 1238m, 1192m, 1150w, 1115w, 1103w,
1094w, 1072w, 1028w, 995w, 974w, 905w, 856s, 787s,781m, 760s, 737s; δH (500 MHz, CDCl3) 8.63 (1H, d,
J 3.5 Hz, Ar H), 8.26–8.25 (2H, m, Ar H), 8.02 (1H, ddd, J 8.0, 8.0, 1.5 Hz, Ar H), 7.80 (1H, d, J 8.0 Hz, Ar
H), 7.66 (1H, d, J 9.5 Hz, Ar H), 7.48–7.46 (4H, m, Ar H), 7.25 (1H, CH, overlap with CDCl3), 6.78 (1H,
d, J 2.0 Hz, CH); δC (125 MHz, CDCl3) 183.2 (s, C=O), 156.5 (s), 154.6 (s), 150.0 (s), 148.5 (d), 141.5 (d),
139.5 (d), 134.3 (s), 133.7 (s), 132.7 (d), 130.6 (d), 128.8 (d), 126.7 (d), 124.3 (d), 120.0 (d), 99.9 (d); m/z
(MALDI-TOF) 302 (MH+ + 1, 16%), 301 (MH+, 100), 300 (M+, 21), 299 (M+ − 1, 39), 272 (16).
1-Phenyl-3-(pyrid-2-yl)benzo[e][1,2,4]triazin-7(1H)-one (4b). To a stirred solution of 1-phenyl-3-
(pyrid-2-yl)-1,4-dihydrobenzo[e][1,2,4]triazin-4-yl (3b) (285 mg, 1.0 mmol) in dichloromethane (10 mL),
MnO2 (896 mg, 10.0 mmol) was added and the reaction mixture was stirred at ca. 20 ◦C for two
days. Upon completion, the reaction mixture was filtered through a short pad of Celite®, rinsed
with additional dichloromethane (50 mL), and volatiles were removed in vacuo. The residue was
chromatographed on a short pad of silica (acetone) to give the title compound 4b (138 mg, 46%) as
purple needles; m.p. (hot-stage): decomp: 199.8–204.0 ◦C (from PhH); m.p. (DSC) decomp. onset:
205.8 ◦C, peak max: 210.8 ◦C (from PhH); Rf 0.69 (CHCl3/MeOH, 80:20); found: C, 71.85; H, 4.13; N,
18.48. C18H12N4O requires C, 71.99; H, 4.03; N, 18.66%; λmax(DCM)/nm 240 (logε 4.15), 300 (4.46), 310
inf (4.41), 338 inf (4.02), 351 inf (4.05), 374 inf (3.75), 534 (3.64), 572 (3.60), 628 inf (3.24); νmax/cm−1
3040w (aryl C-H), 1624m, 1611m, 1589m, 1584m, 1541s, 1537s, 1522m, 1493m, 1477m, 1456m, 1435m,
1395m, 1331m, 1304m, 1233m, 1200m, 1150w, 1117m, 1096w, 1072w, 1045w, 1026w, 995w, 978w, 928w,
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907w, 856s, 822m, 814m, 800m, 779s, 764m, 745m; δH(500 MHz, CDCl3) 8.84 (1H, d, J 4.4 Hz, Ar H),
8.31 (1H, d, J 7.9 Hz, Ar H), 7.88–7.83 (2H, m, Ar H), 7.65–7.55 (5H, m, Ar H), 7.41 (1H, dd, J 6.9, 5.2 Hz,
Ar H), 7.32 (1H, dd, J 9.8, 1.9 Hz, CH), 6.09 (1H, d, J 1.7 Hz, CH); δC(125 MHz, CDCl3) 182.2 (s), 155.3
(s), 151.6 (s), 150.2 (d), 149.8 (s), 142.5 (d), 140.7 (s), 137.0 (d), 136.6 (s), 132.4 (d), 130.3 (d), 130.1 (d),
125.7 (d), 124.7 (d), 122.3 (d), 98.4 (d); m/z (MALDI-TOF) 302 (MH+ + 1, 13%), 301 (MH+, 100), 300 (M+,
19), 285 (19), 273 (28), 242 (35).
3.3. Cell Culture and Cytotoxicity Evaluation
3.3.1. Materials and Cell Lines
2,2,6,6-Tetramethyl-1-piperidinyloxy (TEMPO, CAS number 2564-83-2) was obtained from
Sigma-Aldrich (Darmstadt, Germany). The cytotoxicity evaluation of 1,3-bisphenylbenzo[1,2,4]triazin-
7-one 1 was previously reported [1]. The MCF-7 breast cancer cell line and DU-145 prostate cancer cell
line were obtained from Dr. Stephen Rea, National University of Ireland Galway (Galway, Ireland).
DU-145 was grown in RPMI-1640 medium and supplemented with 1% 2 Mm L-glutamine, 1%
penicillin-streptomycin, and 10% non-heat inactivated fetal bovine serum (FBS). MCF-7 was cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing high glucose (4.5 g/mL) and supplemented
with 1% penicillin-streptomycin and 10% heat-inactivated fetal bovine serum (FBS). All cells grew as
adherent cultures. Cell culture reagents were obtained from Sigma-Aldrich. Disposable sterile plastic
ware was obtained from Sarstedt (Numbrecht, Germany).
3.3.2. Cytotoxicity Measurements Using the MTT Assay
The MTT colorimetric assay was used to determine cell viability [11]. Cells were added to 96-well
plates at a cell density of 1000 cells per well for MCF-7 (200 µL per well) and 2000 cells per well for
DU-145 (200 µL per well), and allowed to adhere over 24 h. Compound solutions were added in
DMSO (1% v/v final concentration in well). The control cells were exposed to the same concentration
of the vehicle control alone (DMSO). All cells were incubated at 37 ◦C and 5% CO2 (humidified
atmosphere) for 72 h. MTT (20 µL, 5 mg/mL solution) was added and the cells were incubated for
a further 3 h. The supernatant was then removed using a multi-transfer pipette and DMSO (100 µL)
added to dissolve the MTT formazan crystals. The absorbance was determined using a plate reader
at 550 nm with a reference at 690 nm. Cell viability is expressed as a percentage of the vehicle-only
treated control (DMSO). Dose-response curves were analyzed by non-linear regression analysis and
IC50 values were determined using GraphPad Prism software, v 8.0 (GraphPad Inc., San Diego, CA,
USA). The in vitro activity of the drugs towards all cell lines is expressed as IC50 (i.e., concentration
required for the reduction of the mean cell viability to 50%).
4. Conclusions
All three stable free radicals evaluated were significantly more cytotoxic towards DU-145 than
the MCF-7 cell line. Benzotriazin-4-yl radicals 3a and 3b were significantly less cytotoxic than their
oxidation products, benzo[1,2,4]triazin-7-ones 4a and 4b, towards the cancer cell lines evaluated.
Pyridyl-substituted benzotriazin-7-ones exhibited submicromolar cytotoxicity using the MTT assay on
par with 1,3-bisphenylbenzo[1,2,4]triazin-7-one 1. The variable DTP-NCI one-dose testing cytotoxicity
profiles for 4a and 4b led to their selection for five-dose testing. COMPARE analysis demonstrated very
strong correlations to pleurotin, despite the overall greater cytotoxicity of the pyrid-2-yl-substituted
compounds compared to 1 after one-dose testing.
Supplementary Materials: Supplementary materials are available online. Figures S1–S4: 1H and 13C-NMR
Spectra for Compounds 4a and 4b, Figure S5–S6: NCI-60 One-Dose Mean Graph Data for Compounds 4a and
4b, Figures S7–S8: NCI-60 Five-Dose Mean Graph Data for Compounds 4a and 4b, Figures S9–S13: Viability of
DU145 and MCF-7 cell lines as determined using the MTT assay for Compounds TEMPO, 3a, 3b, 4a and 4b.
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